ANI PHARMACEUTICALS, INC Long-Term Debt
ANI PHARMACEUTICALS, INC (ANIP) had Long-Term Debt of $280.15 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Long-Term Debt and Lease Obligation
us-gaap:LongTermDebtNoncurrent · last filed 2026-08-07
- 2026-06-30: Long-term Debt, Excluding Current Maturities $280.15M.
- 2026-03-31: Long-term Debt, Excluding Current Maturities $286.00M.
- 2025-12-31: Long-term Debt, Excluding Current Maturities $291.84M.
- 2025-09-30: Long-term Debt, Excluding Current Maturities $297.68M.
| Period end | Long-term Debt, Excluding Current Maturities |
|---|---|
| 2026-06-30 | $280.15M 10-Q · filed 2026-08-07 |
| 2026-03-31 | $286.00M 10-Q · filed 2026-05-08 |
| 2025-12-31 | $291.84M 10-Q · filed 2026-08-07 |
| 2025-09-30 | $297.68M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $301.48M 10-Q · filed 2025-08-08 |
| 2025-03-31 | $305.29M 10-Q · filed 2025-05-09 |
| 2024-12-31 | $309.11M 10-K · filed 2026-02-27 |
| 2024-09-30 | $312.92M 10-Q · filed 2024-11-08 |
| 2024-06-30 | $284.39M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $284.61M 10-Q · filed 2024-05-10 |
| 2023-12-31 | $284.82M 10-K · filed 2025-02-28 |
| 2023-09-30 | $285.03M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $285.24M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $285.46M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $285.67M 10-K · filed 2024-02-29 |
| 2022-09-30 | $285.88M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $286.10M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $286.31M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $286.52M 10-K · filed 2023-03-09 |
| 2021-09-30 | $186.06M 10-Q · filed 2021-11-01 |
| 2021-06-30 | $189.53M 10-Q · filed 2021-08-06 |
| 2021-03-31 | $168.99M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $172.44M 10-K · filed 2022-03-15 |
| 2020-09-30 | $175.16M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $177.88M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $188.09M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $175.81M 10-K · filed 2021-03-11 |
| 2019-09-30 | $64.87M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $65.69M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $66.50M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $67.30M 10-K · filed 2020-02-27 |
| 2018-09-30 | $65.95M 10-Q · filed 2018-11-06 |
| 2018-06-30 | $67.26M 10-Q · filed 2018-08-07 |
| 2018-03-31 | $68.57M 10-Q · filed 2018-05-08 |
| 2017-12-31 | $69.95M 10-K · filed 2019-02-27 |
| 2016-12-31 | $0.00 10-K · filed 2018-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |